<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4792584</article-id><article-id pub-id-type="pmid">26625308</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lue</surname><given-names>Hui-Wen</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cole</surname><given-names>Brook</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rao</surname><given-names>Soumya A. M.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Podolak</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Van Gaest</surname><given-names>Ahna</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>King</surname><given-names>Carly</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eide</surname><given-names>Christopher A.</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wilmot</surname><given-names>Beth</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Changhui</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Spellman</surname><given-names>Paul T.</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Heiser</surname><given-names>Laura M.</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tyner</surname><given-names>Jeffrey W.</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>George V.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A8"><sup>8</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA</aff><aff id="A2"><sup>2</sup> Biomedical Engineering, Oregon Health and Science University, Portland, OR 97239, USA</aff><aff id="A3"><sup>3</sup> Hematology and Oncology, Oregon Health and Science University, Portland, OR 97239, USA</aff><aff id="A4"><sup>4</sup> Howard Hughes Medical Institute, Oregon Health and Science University, Portland, OR 97239, USA</aff><aff id="A5"><sup>5</sup> Oregon Clinical and Translational Research Institute, Oregon Health and Science University, Portland, OR 97239, USA</aff><aff id="A6"><sup>6</sup> Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR 97239, USA</aff><aff id="A7"><sup>7</sup> Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR 97239, USA</aff><aff id="A8"><sup>8</sup> Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, OR 97239, USA</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> George V. Thomas, <email>thomasge@ohsu.edu</email></corresp></author-notes><pub-date pub-type="collection"><day>29</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>26</day><month>11</month><year>2015</year></pub-date><volume>6</volume><issue>42</issue><fpage>44675</fpage><lpage>44687</lpage><history><date date-type="received"><day>22</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>4</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2015 Lue et al.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>The intracytoplasmic tyrosine kinase Src serves both as a conduit and a regulator for multiple processes required for the proliferation and survival cancer cells. In some cancers, Src engages with receptor tyrosine kinases to mediate downstream signaling and in other cancers, it regulates gene expression. Src therefore represents a viable oncologic target. However, clinical responses to Src inhibitors, such as dasatinib have been disappointing to date. We identified Stat3 signaling as a potential bypass mechanism that enables renal cell carcinoma (RCC) cells to escape dasatinib treatment. Combined Src-Stat3 inhibition using dasatinib and CYT387 (a JAK/STAT inhibitor) synergistically reduced cell proliferation and increased apoptosis in RCC cells. Moreover, dasatinib and CYT387 combine to suppress YAP1, a transcriptional co-activator that promotes cell proliferation, survival and organ size. Importantly, this combination was well tolerated, and caused marked tumor inhibition in RCC xenografts. These results suggest that combination therapy with inhibitors of Stat3 signaling may be a useful therapeutic approach to increase the efficacy of Src inhibitors.</p></abstract><kwd-group><kwd>cancer</kwd><kwd>kinase inhibitors</kwd><kwd>kidney</kwd><kwd>Src</kwd><kwd>STAT3</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>In cancer cells, Src is activated nonmutationally through its interaction with growth factor receptors and depending on the context, results in proliferation, survival, growth, adhesion, migration, invasion, angiogenesis and metastases [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R6" ref-type="bibr">6</xref>]. Inhibition of Src therefore represents a promising oncologic therapeutic target and several agents, such as dasatinib, bosutinib and saracatinib have been tested in clinical trials. However clinical responses to these agents have been modest, with rare complete and/or durable responses [<xref rid="R7" ref-type="bibr">7</xref>&#x02013;<xref rid="R23" ref-type="bibr">23</xref>].</p><p>The most commonly used drugs to treat metastatic renal cell carcinoma (RCC) are agents that target VEGF receptors and those that inhibit mTOR. However, while most patients initially respond to these agents the natural history is one of relapse, development of resistance with subsequent disease progression on treatment and death [<xref rid="R24" ref-type="bibr">24</xref>&#x02013;<xref rid="R26" ref-type="bibr">26</xref>]. Thus, to address the unmet need to identify additional targets in RCC, our group and others recently identified Src as a novel therapeutic target in RCC [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>]. Dasatinib alone, however, was cytostatic and failed to kill RCC cells based on <italic>in vitro</italic> and <italic>in vivo</italic> apoptosis assays [<xref rid="R28" ref-type="bibr">28</xref>]. Because of the lack of clinical efficacy of Src inhibitors, our present study sought to identify additional strategies that may increase the effectiveness of Src inhibitors, and importantly reboot the utility of Src inhibitors such as dasatinib in the clinic.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Combined inhibition of Src and Stat3 enhances Src pathway inhibition</title><p>Pre-clinical studies in a wide variety of solid tumors have shown that dasatinib is primarily cytostatic, and this is consistent with the clinical experience, where dasatinib activity is associated with stable disease but complete responses are rarely observed [<xref rid="R7" ref-type="bibr">7</xref>&#x02013;<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R28" ref-type="bibr">28</xref>&#x02013;<xref rid="R33" ref-type="bibr">33</xref>]. Consistent with this, we observed that physiologically relevant doses of dasatinib (~100nM) was effective in reducing the proliferation of the majority of the RCC cell lines (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1</xref>) [<xref rid="R34" ref-type="bibr">34</xref>, <xref rid="R35" ref-type="bibr">35</xref>]. We hypothesized that the purely cytostatic response observed with Src inhibition alone results from bypass survival signaling pathways present in cancer cells that override the therapeutic benefit of dasatinib. Because Stat3 is a known mediator of survival signaling downstream of Src, we decided to test this hypothesis by examining the effect of dasatinib on the levels of phosphorylated Stat3 (hence, activation) [<xref rid="R4" ref-type="bibr">4</xref>]. We observed that dasatinib effectively suppressed phosphorylation of Src and its substrate FAK at low concentrations (i.e. 25&#x02013;100 nM, Figure <xref ref-type="fig" rid="F1">1A</xref> and Figure <xref ref-type="fig" rid="F2">2C</xref>). Surprisingly, dasatinib failed to abrogate the phosphorylation of Stat3 in all of the cell lines in our panel, and in some cell lines resulted in higher levels of Stat3 phosphorylation (for example TK10 and SN12C). Stat3 has been shown to promote cell survival and induce drug resistance in cancer cells [<xref rid="R34" ref-type="bibr">34</xref>, <xref rid="R36" ref-type="bibr">36</xref>&#x02013;<xref rid="R39" ref-type="bibr">39</xref>]. Together, these findings suggest that although dasatinib effectively dephosphorylates Src, there is persistence of Stat3 signaling, which may mediate dasatinib-independent survival signals.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Dasatinib inhibits Src signaling, but not STAT3 activation in RCC cells lines</title><p>RCC cell lines were treated for 24 hours with the indicated concentrations of either <bold>A.</bold> dasatinib or <bold>B.</bold> CYT387, and lysates were probed with the indicated antibodies. Actin was used as loading control.</p></caption><graphic xlink:href="oncotarget-06-44675-g001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Src and STAT3 are synergistic targets in RCC</title><p><bold>A. Left:</bold> Dose response curves in the presence of various doses of CYT387 and dasatinib in Caki-1, TK10 and ACHN RCC cell lines; <bold>Middle:</bold> heatmap of growth inhibition, and <bold>Right:</bold> heatmap of Bliss Scores: CAKI-1: 215; TK10: 621; ACHN: 454. <bold>B.</bold> Growth of RCC cells were analyzed after 5 days of treatment with dasatinib and CYT387. Combination index (CI) were determined by using the Chou-Talalay method (CompuSyn software) for drug combinations with a fractional effect (FA) between 0.2 and 0.9 (20&#x02013;90% of cell growth inhibition relative to control). CI values &#x0003c; 1 indicates drug synergy. <bold>C.</bold> RCC cells were treated with 100nM of dasatinib and 2 &#x003bc;M of CYT387, alone, in combination or DMSO for 24 hours and lysates were probed with the indicated antibodies. <bold>D.</bold> Twelve RCC cell lines were treated with dasatinib, CYT387 or the combination for 72 hours and apoptotic cells were determined by Caspase 3/7 activation (Caspase-Glo assay). For each cell line, the fold change in apoptosis is color-coded. The percentage of all cell lines exhibiting the indicated degree of apoptosis is shown.</p></caption><graphic xlink:href="oncotarget-06-44675-g002"/></fig><p>To test the role of Stat3 in overriding dasatinib inhibition, we treated the RCC cells with CYT387 (Momelotinub <sup>&#x000ae;</sup>), a JAK-STAT inhibitor that is currently in clinical trials for myeloproliferative neoplasia [<xref rid="R40" ref-type="bibr">40</xref>]. Accordingly, CYT387 treatment led to suppression of Stat3 phosphorylation in RCC cells (Figure <xref ref-type="fig" rid="F1">1B</xref>). We next determined whether the co-targeting of Src and Stat3 exhibited synergistic activity in RCC cancer cells by treating each of the cell lines with increasing concentrations of dasatinib and CYT387 alone and in combination. We used a dose matrix to sample a large range of concentrations and concentration ratios and analyzed combination effects using the Bliss independence model [<xref rid="R41" ref-type="bibr">41</xref>]. Positive Bliss scores indicate combination effects where the effect is greater than additive. The heatmaps for CAKI-1, TK-10 and ACHN show that there are positive Bliss scores across a large range of concentration for both compounds (Figure <xref ref-type="fig" rid="F2">2A</xref>). Next we confirmed our findings using the Chou-Talalay analysis to test for synergy. Dasatinib and CYT387 combinations in 9 out of 12 cell lines (for example, CAKI-1, ACHN, TK10, SN12C) demonstrated a combination index (CI) of less than 1.0, indicating synergy (Figure <xref ref-type="fig" rid="F2">2B</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 2</xref>). Stat3 phosphorylation was inhibited in cell lines exhibiting synergy to the dasatinib and CYT387 combinations (for example CAKI-1, TK-10, ACHN and SN12C) as well as those that were additive or antagonistic (for example UO31 and A498, respectively; Figure <xref ref-type="fig" rid="F2">2C</xref>). These findings suggest that, although inhibition of p-Src and p-Stat3 are clearly necessary, it alone is not sufficient to predict synergy to the combination therapy.</p><p>Moreover, combined treatment with dasatinib and CYT387 caused a marked increase in apoptosis in the majority of RCC cells in the panel compared to dasatinib alone (Figure <xref ref-type="fig" rid="F2">2D</xref>). Together, these data demonstrate that Stat3 inhibition enhanced the effects of dasatinib in RCC cells.</p></sec><sec id="s2_2"><title>Combined inhibition of Src and Stat3 reduces tumor growth</title><p>We next examined the safety and efficacy of inhibiting Src and Stat3 <italic>in vivo</italic> in two xenograft tumor models. While dasatinib or CYT387 alone exhibited anti-tumor effect on CAKI-1 and ACHN xenografts, the combination of dasatinib with CYT387 resulted in significantly greater tumor growth inhibition (71% TGI) in CAKI-1 and (48% TGI) in ACHN tumor xenografts (<italic>p &#x0003c; 0.001;</italic> Figure <xref ref-type="fig" rid="F3">3A and 3B</xref>, respectively). Importantly, combination treatment was well tolerated, with no weight loss recorded (Figure <xref ref-type="fig" rid="F3">3C and 3D</xref>, respectively). Pharmacodynamic studies demonstrated that combination therapy led to the suppression of Stat3 and Src phosphorylation (Figure <xref ref-type="fig" rid="F3">3E and 3F</xref>, respectively). Consistent with our prior finding, dasatinib alone had minimal impact on apoptosis [<xref rid="R28" ref-type="bibr">28</xref>]. In marked contrast, combination treatment with dasatinib and CYT387 resulted in significant increase in apoptosis (demonstrated by increase in cleaved-caspase3, <italic>p &#x0003c; 0.001</italic>; Figure <xref ref-type="fig" rid="F3">3G</xref>) and reduction in proliferation (demonstrated by decrease in Ki-67, <italic>p &#x0003c; 0.001</italic>; Figure <xref ref-type="fig" rid="F3">3H</xref>). Therefore, prolonged inhibition of Src and Stat3 signaling by combining dasatinib and CYT387 is associated with enhanced inhibition of tumor growth with good tolerability.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title><italic>In Vivo</italic> efficacy of combined Src and STAT3 inhibition</title><p><bold>A.</bold> CAKI-1 and <bold>B.</bold> ACHN xenografts were treated with vehicle (control), dasatinib (25mg/kg/day), CYT387 (50mg/kg/day) or both drugs in combination Tumor volume is shown. Error bars represent mean &#x000b1; SEM. * denotes <italic>P</italic> &#x0003c; 0.05, ** denotes <italic>P</italic> &#x0003c; 0.01, and *** denotes <italic>P</italic> &#x0003c; 0.001. Body weights of mice bearing <bold>C.</bold> Caki-1, and <bold>D.</bold> ACHN tumors as indicated. Data are presented as mean &#x000b1; SEM. <italic>ns</italic> denotes not significant. <bold>E&#x02013;H.</bold> Tumor tissue from CAKI-1 and ACHN xenografts treated with the indicated drug regimens were evaluated by immunohistochemistry for (E) p-STAT3; (F) p-SRC; (G) cleaved-Caspase 3 (a marker of apoptosis), and (H) Ki-67 (a marker of proliferation). Error bars represent mean &#x000b1; SEM. * denotes <italic>P</italic> &#x0003c; 0.05, ** denotes <italic>P</italic> &#x0003c; 0.01, and *** denotes <italic>P</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="oncotarget-06-44675-g003"/></fig></sec><sec id="s2_3"><title>Dasatinib and CYT arrests YAP1 transcriptional programs</title><p>We observed that a lack of response, and subsequently synergy to the dasatinib and CYT387 combination treatment in several cell lines despite robust p-Src and p-Stat3 inhibition that was comparable to that achieved in synergistic cell lines (Figure <xref ref-type="fig" rid="F2">2C, 2D</xref>). These findings suggest that despite on-target inhibition by dasatinib and CYT387, suppression of Src and Stat3 activation are not sufficient to predict sensitivity to this combination. To identify potential signaling pathways downstream of combined dasatinib+CYT387 treatment that have greater fidelity for predicting synergistic response, we performed reverse phase protein array (RPPA) analysis and the fold changes were translated to a z-score (<italic>see Methods</italic>). Strikingly, we observed that the levels of phosphorylated Serine 127-YAP1 (Yes-associated protein 1) increased by approximately 6- and 2-fold in the combination treatment compared to vehicle control in ACHN and SN12C cells, respectively (Figure <xref ref-type="fig" rid="F4">4A</xref>).</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Dasatinib and CYT387 combine to inhibit YAP dependent transcription</title><p><bold>A.</bold> Heatmap of total or phosphorylated protein abundance from each of the different samples (ACHN or SN12C that were treated with dasatinib, CYT387 or the combination of both drugs for 24 hrs) determined by RPPA. Insert depicts p-Ser127YAP1 and total YAP1 levels. <bold>B.</bold> Western blots of p-Ser127 YAP1 and total YAP1, p-FAK, p-STAT3 treated with the indicated drugs for 24 hours in ACHN, SN12C and RXF393 RCC cells. <bold>C.</bold> Heatmap of YAP1 regulated genes in ACHN cells after treatment with dasatinib, CYT387 or the combination of both drugs, as analyzed by RNA-Seq. <bold>D.</bold> Western blots of CDKN1B (p27) in ACHN cells. Actin is used as loading control. <bold>E.</bold> Kaplan-Meier survival plots as a function of relative expression of <italic>YAP1</italic> and <italic>TAZ</italic> mRNA in the TCGA kidney cancer cohort of 499 patient tumors (<italic>p</italic> = 7.467e-4). <bold>F&#x02013;G.</bold> GSEA plots of the ranked list of differentially expressed genes between dasatinib and CYT387 co-treatment (Das+CYT387) and vehicle (Veh), using two genesets: (F) YAP-downregulated, and: (G) YAP-upregulated. <bold>H. Left</bold>: Table of gene sets from MSigDB (C2) collection enriched among genes downregulated by the dasatinib-CYT387 combination treatment in ACHN cells with normalized enrichment score (NES) ranked by FDR <italic>q</italic> value; <bold>Right</bold>: examples of GSEA plots of genes regulating transcription/translation in ACHN cells that are downregulated by the dasatinib and CYT387 combination therapy.</p></caption><graphic xlink:href="oncotarget-06-44675-g004"/></fig><p>Phosphorylation at Ser127 of YAP1 results in its sequestration in the cytoplasm and subsequent degradation. YAP1 regulates several context-specific transcriptional programs that promotes tumor proliferation, survival and organ growth, and is an effector of the canonical Hippo signaling pathway that comprises a cascade of kinases that includes the Hippo/MST1&#x02013;2 kinases, the adaptor Sav1, and the LATS1/2 kinases [<xref rid="R42" ref-type="bibr">42</xref>]. When the Hippo signaling is turned on, it culminates in the phosphorylation and consequent inactivation of the transcriptional co-activators YAP1 and transcriptional co-activator with PDZ-binding motif (TAZ) by LATS1/2, which suppresses the TEA domain-containing sequence-specific transcription factors (TEADs)-dependent expression of a network of genes that promote cell proliferation and survival. Studies in mouse models have shown that YAP1 functions as an oncogene [<xref rid="R43" ref-type="bibr">43</xref>, <xref rid="R44" ref-type="bibr">44</xref>]. The increase in p-Ser127YAP1 levels in ACHN and SN12C cells, which are both synergistic to the dasatinib-CYT387 combination, was confirmed through Western blot analysis (Figure <xref ref-type="fig" rid="F4">4B</xref>). Notably, the combination of dasatinib and CYT387 in ACHN and SN12C cells induced greater phosphorylation of Ser127YAP1 than either drug alone, indicating that CYT387 and dasatinib affect YAP1 via a parallel pathway. In contrast, p-Ser127YAP1 levels did not increase in RXF393 cells, which exhibit antagonism to, and are resistant to apoptosis when co-treated with dasatinib and CYT387 (Figure <xref ref-type="fig" rid="F2">2B and 2D</xref>).</p><p>To further investigate the transcriptional responses to YAP1 inactivation, we analyzed the RNA sequencing (RNA-Seq) profiles of ACHN cells treated with dasatinib and CYT387 (Figure <xref ref-type="fig" rid="F4">4C</xref>). Consistent with the decrease in YAP1 activation, we observed an increase in YAP1 gene targets that encode for inhibition of the cell cycle, such as CDKN1A and CDKN1B; and similarly, a decrease in those that encode for cell cycle progression, such as CDK1, with the combination therapy of dasatinib and CYT387 having greater effect on gene expression than either drug alone [<xref rid="R45" ref-type="bibr">45</xref>]. The gain in <italic>CDKN1B (p27)</italic> transcripts in ACHN cells with dasatinib and CYT387 co-treatment corresponded with an increase at the protein level (Figure <xref ref-type="fig" rid="F4">4D</xref>).</p><p>Then in a cohort of 499 patients from the TCGA RCC dataset [<xref rid="R46" ref-type="bibr">46</xref>], we found that high levels of <italic>YAP1</italic> and <italic>TAZ</italic> transcripts itself, as well as its regulated genes <italic>CDK1, AURKA, AURKB, CCNB1 and CCNB1</italic> are associated with poor prognosis (Figure <xref ref-type="fig" rid="F4">4E</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 3</xref>).</p><p>Next, using gene set enrichment analysis (GSEA), we evaluated two canonical transcriptional signatures of YAP1-dependent genes in ACHN cells treated with dasatinib and CYT387 compared to vehicle [<xref rid="R47" ref-type="bibr">47</xref>]. Remarkably, the genes downregulated by YAP1 knockdown [<xref rid="R48" ref-type="bibr">48</xref>] were significantly enriched by dasatinib and CYT387 combination treatment (Normalized Enrichment Score = +1.84, where positive values indicate correlation; <italic>P</italic> = 0.023; False Discovery Rate = 0.069) (Figure <xref ref-type="fig" rid="F4">4F</xref>). Correspondingly, the genes that are positively regulated by YAP1 [<xref rid="R49" ref-type="bibr">49</xref>] were downregulated and significantly enriched by dasatinib and CYT387 combination treatment (NES = &#x02212;3.14, where negative values indicate anticorrelation; <italic>P</italic> = 0.0; FDR = 0.0) (Figure <xref ref-type="fig" rid="F4">4G</xref>), suggesting a strong correlation with YAP1 transcriptional signatures and Src and Stat3 inhibition.</p><p>Next, we performed GSEA on the entire Molecular Signature Database (MSigDB: C2 canonical pathway dataset). Genesets related to inhibition of cell cycle, transcription and translation were significantly enriched in the dasatinib and CYT 387 co-treatment suppressed genes (Figure <xref ref-type="fig" rid="F4">4H</xref> and <xref ref-type="supplementary-material" rid="SD2">Supplemental Table 1</xref>). Specifically, biological modules associated with YAP1 (e.g. cell cycle checkpoints, synthesis of DNA) were also anticorrelated with dasatinib and CYT387 co-treatment. Together, these data support the observation that Src and Stat3 inhibition confers a selective repression of transcriptional networks induced by YAP1.</p></sec></sec><sec id="s3"><title>DISCUSSION</title><p>The goal of the present study was to identify ways to improve the initial responses to Src inhibitors. Since Src functions primarily as a signaling rheostat, we hypothesized that Src is best targeted in combination with agents that inhibit molecules that signal through, or engage with it. We observed that dasatinib potently inhibited Src signaling, as demonstrated by suppressed Src and FAK phosphorylation but that the activity of Stat3 persisted, probably through input from other pathways. Cumulative evidence supports activation of Stat3 as an oncogenic pathway in many cancers, including RCC [<xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R50" ref-type="bibr">50</xref>&#x02013;<xref rid="R53" ref-type="bibr">53</xref>]. Importantly, persistent activation of Stat3 has been implicated in conferring resistance to some anticancer drugs [<xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R54" ref-type="bibr">54</xref>, <xref rid="R55" ref-type="bibr">55</xref>]. Stat3 activation potentiates both proliferative and anti-apoptotic signaling and is associated with chemoresistance. In addition, studies in head and neck and non-small cell lung cancer cells have shown reactivation of Stat3 signaling in the presence of dasatinib, indicating that these cancers have become resistant to dasatinib by finding a way to sustain Stat3 signaling [<xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R56" ref-type="bibr">56</xref>].</p><p>Since developing drugs that target transcription factors such as Stat3 has so far been challenging, small molecule JAK inhibitors represent a plausible clinical alternative to block Stat3 signaling. [<xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R55" ref-type="bibr">55</xref>, <xref rid="R57" ref-type="bibr">57</xref>]. We demonstrated that full suppression of Stat3 activation was achieved with the addition of a JAK inhibitor, CYT387. Importantly, CYT387 synergized with dasatinib in cell lines and in mouse xenografts models to inhibit proliferation, induce apoptosis and suppress tumor growth.</p><p>An unexpected finding was the pronounced and concordant increase in Ser127YAP1 phosphorylation by dasatinib and CYT38 with the subsequent suppression of multiple YAP1-dependent transcriptional signatures. Previous reports have documented a role for Yes1 (a Src family kinase member) in phosphorylating Y357YAP1, which results in its nuclear localization and transcriptional activation, which was then inhibited by the addition of dasatinib [<xref rid="R58" ref-type="bibr">58</xref>]. While the mechanism(s) mediating an increase in the serine-127 phosphorylation of YAP1 and thereby preventing its nuclear translocation is unknown, it may suggest that both dasatinib and CYT387 positively impact the Hippo signaling cascade with resultant inhibition of cell proliferation and growth. These observations are compatible with the known role of YAP1 as transcriptional regulator of cell proliferation and tumor cell survival and importantly, the RNA-Seq analysis of YAP1 target genes in the TCGA RCC dataset suggests that several YAP1-TAZ regulated genes are associated with poor prognosis of RCC patients.</p><p>In summary, we observed synergistic activity with dasatinib and CYT387, and these findings point to a strategy to potentially improve the efficacy of Src inhibitors by co-treatment with Stat3 inhibitors.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Cell lines</title><p>ACHN, A498, Caki-1, RCC4, RCC10, RXF393, SN12C, TK-10, U031, 786&#x02013;0 were used in this study and were obtained from the ATCC. RCC10+VHL and 786+VHL were stably transfected with wild type VHL. Cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37&#x000b0;C in a 5% CO<sub>2</sub> incubator.</p></sec><sec id="s4_2"><title>Cell viability and apoptosis analysis</title><p>Cell viability assays were performed by plating 3*10<sup>3</sup> cells/well in 24-well plates in triplicate and treating the following day with the indicated agent. The experiment was continued for 5 days and then the cells were fixed using 4% formaldehyde and stained for 1 hour with Syto60. Fluorescence was measured and quantified and photographs were obtained using a LiCor Odyssey Infrared Imager. Experimental results are the average of at least three independent experiments.</p><p>Apoptosis was determined using Caspase 3/7-Glo assay kit (Promega) following the manufacturer's instructions. Briefly, 1 &#x000d7; 10<sup>3</sup> cells per well were plated in 96 well plates and cultured for 24 h. Cells were treated with dasatinib, CYT387 and the combination of dasatinib and CYT387 for &#x02212;72 h, and then 100 &#x003bc;l reagents were added to each well and incubated for 30 min at room temperature. Caspase 3/7 activity was measured using a luminometer. Luminescence values were normalized by cell numbers. The effect of dasatinib, CYT387 and the dasatinib+CYT387 combination on caspase 3/7 activation was assessed as fold of DMSO-treated control cells.</p></sec><sec id="s4_3"><title>Drug combination studies</title><p>Cells were seeded in 384-well plates at 500 cells/well. After 24 hours, cells were treated with dasatinib (dose range of 0&#x02013;400 nM) and CYT387 (dose range of 0&#x02013;3.5 &#x003bc;M) in a 10 by 5 matrix. Cells were treated for 120 hours, and ATP was determined with CellTiter-Glo (Promega). Dasatinib IC<sub>50</sub> values were calculated from the 6 single-agent doses using a 3-parameter fit with XLFit (IDBS). The Bliss expectation was calculated with the equation (A+B) - (A*B), where A and B are the fractional growth inhibitions induced by agents A and B at a given dose. The difference between Bliss expectation and observed growth inhibition induced by the combination of agents A and B is the &#x0201c;Bliss scores&#x0201d;. &#x0201c;Bliss sum&#x0201d; is the sum of all Bliss scores in a given matrix. Combination indices (CI) were calculated using Calcusyn software. A CI value less than 1.0 is represents a synergistic drug combination.</p></sec><sec id="s4_4"><title>Western blotting</title><p>Cells were plated in 6 well dishes and treated the following day with the indicated agents. Treatments were for 24 hours, after which cells were washed with ice cold PBS and, unless otherwise indicated, lysed with Additionally, 0.5 mM DTT, 4 &#x003bc;g/mL leupeptin, 4 &#x003bc;g/mL pepstatin, 4 &#x003bc;g/mL aprotinin, RIPA buffer (Sigma). Phosphatase inhibitor cocktail set II and protease inhibitor cocktail set III (EMD Millipore) were added at the time of lysis. Lysates were centrifuged at 15,000g &#x000d7; 10 min at 4 degrees C. Protein concentrations were calculated based on a BCA assay (Thermo Scientific) generated standard curve. Proteins were resolved using the NuPAGE Novex Mini Gel system on 4% to 12% Bis-Tris Gels (Invitrogen). For western blotting, equal amounts of cell lysates (15&#x02013;20 &#x003bc;g of protein) were resolved with SDS-PAGE, and transferred to membranes. The membrane was probed with primary antibodies, washed, and then incubated with corresponding fluorescent secondary antibodies and washed. The fluorescent signal was captured using LI-COR (Lincoln, NE) Odyssey Imaging System, and fluorescent intensity was quantified using the Odyssey software where indicated. The following antibodies were used for Western blots: p-Src (Y416), Src, p-Fak (Y576/577), Fak, Jak2, p-YAP1 (S127), and YAP1 (Cell Signaling Technologies). p-Jak2 (Y1007/1008), pStat3 (Y705), Stat3 and &#x003b2;-actin (AC15) (Abcam). Ki67 (Dako) and cleaved caspase3 (Cell Signaling Technologies) were used for immunohistochemistry. Dasatinib and CYT387 for <italic>in vitro</italic> and <italic>in vivo</italic> use were purchased from LC Labs and ChemieTek, respectively.</p></sec><sec id="s4_5"><title><italic>In vivo</italic> xenograft studies</title><p>4&#x02013;6 week old mice were utilized for human renal cell carcinoma xenografts. For both ACHN and Caki-1 cell lines 1 &#x000d7; 10<sup>6</sup> cells were diluted in 50 &#x003bc;l of PBS and 50 &#x003bc;l of Matrigel (BD Biosciences) and were injected subcutaneously into the right and left flank of each mouse.</p><p>Tumors were monitored until they reached an average size of 50&#x02013;80 mm<sup>3</sup> (approximately 2 weeks), at which point treatments were begun. Dasatinib (25 mg/kg/day) and CYT387 (50 mg/kg/day) were administered by oral gavage 5 day/week. Dasatinib was dissolved in 1-Methyl-2-pyrrolidinone (NMP, sigma)/Propylene glycol (Sigma) and CYT387 was dissolved in NMP/Captisol (Cydex). Tumors and mouse weights were measured twice weekly. At least 6&#x02013;8 mice per treatment group were included. All mice were euthanized using CO<sub>2</sub> inhalation followed by cervical dislocation per institutional guidelines at Oregon Health and Science University. Experiments were approved by the Institutional Animal Care and Use Committee at OHSU.</p></sec><sec id="s4_6"><title>Immunohistochemistry studies</title><p>Immunostaining was performed following deparaffinization and rehydration of the slides, antigen retrieval was performed in a pressure cooker using citrate buffer (pH 6.0) for 4 min. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 15 min at room temperature and nonspecific binding was blocked using 10% normal horse serum for 30 min at room temperature. Samples were incubated at room temperature with p-Y416Src rabbit monoclonal antibody (Y416), cleaved caspase 3, p-Y705Stat3 and Ki67. Slides were developed with Vector Immpress rabbit IgG (#MP7401) and Vector Immpress mouse IgG (#MP7400) for 30 min at room temperature. Chromogenic detection was performed using Vector Immpact DAB (#SK4105) for 3 min. Sides were counterstained with hematoxylin. A 3DHistech MIDI Scanner (Perkin Elmer) was used to capture whole slide digital images with a 20x objective. Images were converted to into MRXS files and computer graphic analysis was completed using inForm 1.4.0 Advanced Image Analysis Software (Perkin Elmer).</p></sec><sec id="s4_7"><title>Statistical analysis</title><p>Mouse tumor size was analyzed by 2-way ANOVA with time and drug as factors, using GraphPad Prism. Mouse weight during treatment was analyzed by repeated measures 2-way ANOVA, with time and drug as factors. A <italic>P</italic> value less than 0.05 was considered statistically significant. Immunohistochemistry: <italic>P</italic>-values were calculated using one-way ANOVA, with Bonferroni's multiple comparison test. * denotes <italic>P</italic> &#x0003c; 0.05, ** denotes <italic>P</italic> &#x0003c; 0.01, and *** denotes <italic>P</italic> &#x0003c; 0.001.</p></sec><sec id="s4_8"><title>Reverse phase protein array</title><p>Cell lines were either treated with DMSO, 100 nM dasatinib, 2 &#x003bc;M CYT387, or the combination of dasatinib and CYT387 for 24 h. Lysates were prepared as recommended by MD Anderson Cancer Center (Houston, Texas, USA), arrayed on nitrocellulose-coated slides, probed for a standard list of antibodies at the MD Anderson Cancer Center and results were quantified and normalized using their procedure [<xref rid="R59" ref-type="bibr">59</xref>]. Genes with insufficient signal were filtered out. From the quantile normalized RPPA data, the fold change values were calculated (the ratio of drug treated above the vehicle treated) for three treatments: dasatinib, CYT387 and combination of dasatinib+CYT387. We calculated the z-score for the protein fold changes from the RPPA data. Z-scores were calculated from the log2 fold change values. Z-score = (log2 fold change of protein&#x02014;mean of log2 fold changes of all proteins of the array) / standard deviation of log2 fold changes of all proteins of the array. We applied a z-score cutoff of &#x000b1; 1.96 for the both cell lines. The proteins/phosphoproteins with a z-score of &#x0003e; 1.96 or &#x0003c;&#x02013;1.96 in both cell lines were selected. The fold change values were visualized by generating the heatmap using MeV software (<ext-link ext-link-type="uri" xlink:href="http://www.tm4.org/mev.html">http://www.tm4.org/mev.html</ext-link>).</p></sec><sec id="s4_9"><title>RNA Seq analysis</title><p>Total RNA was extracted from ACHN cells treated with 50nM of dasatinib and 2uM of CYT387, alone, in combination or DMSO for 24 hours. Total RNA was extracted with Trizol/CHCl3 (Life Technologies) according to the manufacturer's protocol. The aqueous phase was put through the Qiagen RNEasy kit for cleanup. Sample preparation followed the Agilent SureSelect Strand-Specific mRNA Library Preparation Protocol (Version A.2, September 2013, Agilent Technologies, Santa Clara, CA). Poly-A RNA was purified from 1ug total RNA per sample using two serial rounds of binding to oligo dT magnetic beads. The poly(A) RNA was chemically-fragmented and first-stand cDNA was synthesized using the RNA Seq First Strand Master Mix (Agilent). After purifying the first strand cDNA using AMPure XP beads, second-strand cDNA was synthesized and ends were repaired. A second round of cDNA purification with AMPure XP beads occurred, the 3&#x02032; ends were adenylated, followed by adapter ligation and AMPure XP beads purification. Ligated DNA was PCR amplified for 14 cycles and purified again with AMPure XP beads. Quality of the resulting libraries was assessed with an Agilent 2100 Bioanalyzer DNA 1000 Assay. Libraries were sequenced on an Illumina (San Diego, CA) HiSeq as single-end 50bp reads. Sequence data are available at Gene Expression Omnibus with accession number pending.</p><p>Fastq files were re-aligned to the human genome GRCh37.70 with the subjunc function in the Subread package allowing for 5 bp indels and all possible junctions [<xref rid="R60" ref-type="bibr">60</xref>]. Reads were assigned to genes and counted using the Featurecounts function of subread [<xref rid="R61" ref-type="bibr">61</xref>]. The aligned reads are summarized over exons to obtain number of reads mapping to each union exon (count data) using a custom python script. First, a GTF formatted annotation file is parsed to create union exon ranges. Secondly, the exon boundaries and an alignment in SAM format were read and the number of reads falling in each of the defined exonic regions was counted. Samples were investigated for anomalies or differences that would preclude incorporation in to the final dataset using custom scripts in the R statistical programming language (<ext-link ext-link-type="uri" xlink:href="http://www.R-project.org">http://www.R-project.org</ext-link>). Very lowly expressed tags i.e. tags which have fewer than 5 counts in total were excluded. Different samples might be sequenced with different depths or depending on the tissue type some genes may be highly expressed. To account for this the count data is normalized using the upper quartile method that adjusts the top 75th percentile across all samples (R package EdgeR, <ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org">http://www.bioconductor.org</ext-link>).</p><p>TCGA KIRC data was stratified by YAP1 and TAZ mRNA expression using the cBio Cancer Genomics Portal platform (<ext-link ext-link-type="uri" xlink:href="http://cbioportal.org">http://cbioportal.org</ext-link>).</p></sec><sec id="s4_10"><title>Gene set enrichment analysis</title><p>Normalized counts/million (cpm) values from RNAseq data were used for calculating the fold change values using the vehicle treated sample as reference. The fold change values for 1.5-fold regulated genes were used for Gene Set Enrichment Analysis (GSEA) using the Pre-ranked option (GSEA-P) in GSEA v2.1.0 software as described in [<xref rid="R47" ref-type="bibr">47</xref>]. Analysis was performed on C2-canonical pathways defined in MSigDB (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=CP">http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=CP</ext-link>) with a weighted enrichment statistic. One thousand permutations of the data were completed to obtain an FDR <italic>q</italic> value. Significance was defined as having an FDR <italic>q</italic> value &#x0003c; 0.25. GSEA was performed independently for three treatments, i.e.: dasatinib, CYT387 and dasatinib+CYT387 and significant genesets were compared.</p><p>To specifically look at effect of combination treatment on YAP1, we performed GSEA analysis focusing on YAP1 targets. We defined three genesets as readouts for YAP1 activity:<list list-type="order"><list-item><p>&#x0201c;REACTOME_YAP1_AND_WWTR1_TAZ_STIMULATED_GENE_EXPRESSION&#x0201d; defined as genes involved in YAP1- and WWTR1 (TAZ)-stimulated gene expression from MSigDB,</p></list-item><list-item><p>&#x0201c;YAP1_TARGETS_AVNISHKAPOOR&#x0201d; defined as genes upregulated in YAP1 overexpressing mouse pancreatic tumors [<xref rid="R49" ref-type="bibr">49</xref>] and, 3) &#x0201c;YAP1_TARGETS_DIANE_SHAO&#x0201d; defined as genes downregulated in HCTtetK cells stably expressing YAP1 (data from GSE55942) as described in [<xref rid="R48" ref-type="bibr">48</xref>].</p></list-item></list></p><p>For YAP1, we performed GSEA analysis on all the genes from the RNAseq data using phenotype permutation with a weighted enrichment statistic and a signal-to-noise metric for ranking genes.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY FIGURES AND TABLE</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-06-44675-s001.pdf" orientation="portrait" xlink:type="simple" id="d36e852" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-06-44675-s002.xlsx" orientation="portrait" xlink:type="simple" id="d36e854" position="anchor"/></supplementary-material></sec></body><back><ack><title>ACKNOWLEDGMENTS AND FUNDING</title><p>We thank Mandy Burns, Christine Koontz and Bill Hrdina for administrative support; the Histopathology Shared Resource for pathology support and Integrated Genomics Shared Resource for RNA sequencing; and the Oregon Translational Research and Development Institute (OTRADI) for high throughput drug screening support.</p></ack><fn-group><fn fn-type="conflict"><p><bold>CONFLICTS OF INTEREST</bold></p><p>The authors declare that they have no competing interest.</p></fn><fn fn-type="supported-by"><p><bold>GRANT SUPPORT</bold></p><p>This study was supported by NIH grants R01 CA169172, P30 CA069533 and P30 CA069533 13S5 through OHSU-Knight Cancer Institute, The Hope Foundation (SWOG), OTRADI and Kure It Cancer Research (G.V. T).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abram</surname><given-names>CL</given-names></name><name><surname>Courtneidge</surname><given-names>SA</given-names></name></person-group><article-title>Src family tyrosine kinases and growth factor signaling</article-title><source>Exp Cell Res</source><year>2000</year><volume>254</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10623460</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bromann</surname><given-names>PA</given-names></name><name><surname>Korkaya</surname><given-names>H</given-names></name><name><surname>Courtneidge</surname><given-names>SA</given-names></name></person-group><article-title>The interplay between Src family kinases and receptor tyrosine kinases</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>7957</fpage><lpage>7968</lpage><pub-id pub-id-type="pmid">15489913</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irby</surname><given-names>RB</given-names></name><name><surname>Yeatman</surname><given-names>TJ</given-names></name></person-group><article-title>Role of Src expression and activation in human cancer</article-title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>5636</fpage><lpage>5642</lpage><pub-id pub-id-type="pmid">11114744</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>LC</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Haura</surname><given-names>EB</given-names></name></person-group><article-title>Src kinases as therapeutic targets for cancer</article-title><source>Nat Rev Clin Oncol</source><year>2009</year><volume>6</volume><fpage>587</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">19787002</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopetz</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>AN</given-names></name><name><surname>Gallick</surname><given-names>GE</given-names></name></person-group><article-title>Src continues aging: current and future clinical directions</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>7232</fpage><lpage>7236</lpage><pub-id pub-id-type="pmid">18094400</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeatman</surname><given-names>TJ</given-names></name></person-group><article-title>A renaissance for SRC</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>470</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">15170449</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>HD</given-names></name><name><surname>Glisson</surname><given-names>BS</given-names></name><name><surname>Bekele</surname><given-names>BN</given-names></name><name><surname>Johnson</surname><given-names>FM</given-names></name><name><surname>Ginsberg</surname><given-names>LE</given-names></name><name><surname>El-Naggar</surname><given-names>A</given-names></name><name><surname>Culotta</surname><given-names>KS</given-names></name><name><surname>Takebe</surname><given-names>N</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>HT</given-names></name><name><surname>Papadimitrakopoulou</surname><given-names>VA</given-names></name></person-group><article-title>Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma</article-title><source>Cancer</source><year>2011</year><volume>117</volume><fpage>2112</fpage><lpage>2119</lpage><pub-id pub-id-type="pmid">21523723</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudek</surname><given-names>AZ</given-names></name><name><surname>Pang</surname><given-names>H</given-names></name><name><surname>Kratzke</surname><given-names>RA</given-names></name><name><surname>Otterson</surname><given-names>GA</given-names></name><name><surname>Hodgson</surname><given-names>L</given-names></name><name><surname>Vokes</surname><given-names>EE</given-names></name><name><surname>Kindler</surname><given-names>HL</given-names></name><collab>Cancer, Leukemia Group B</collab></person-group><article-title>Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report</article-title><source>J Thorac Oncol</source><year>2012</year><volume>7</volume><fpage>755</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">22425926</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Bengala</surname><given-names>C</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Roche</surname><given-names>H</given-names></name><name><surname>Sparano</surname><given-names>J</given-names></name><name><surname>Strauss</surname><given-names>LC</given-names></name><name><surname>Fairchild</surname><given-names>J</given-names></name><name><surname>Sy</surname><given-names>O</given-names></name><name><surname>Goldstein</surname><given-names>LJ</given-names></name></person-group><article-title>Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>6905</fpage><lpage>6913</lpage><pub-id pub-id-type="pmid">22028489</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>KA</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Harun</surname><given-names>N</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Price</surname><given-names>J</given-names></name><name><surname>Kawedia</surname><given-names>JD</given-names></name><name><surname>Tran</surname><given-names>HT</given-names></name><name><surname>Erasmus</surname><given-names>JJ</given-names></name><name><surname>Blumenschein</surname><given-names>GR</given-names></name><name><surname>William</surname><given-names>WN</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Johnson</surname><given-names>FM</given-names></name></person-group><article-title>A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer</article-title><source>Oncologist</source><year>2014</year><volume>19</volume><fpage>1040</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">25170013</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubens</surname><given-names>MA</given-names></name><name><surname>Burns</surname><given-names>M</given-names></name><name><surname>Perkins</surname><given-names>SM</given-names></name><name><surname>Pedro-Salcedo</surname><given-names>MS</given-names></name><name><surname>Althouse</surname><given-names>SK</given-names></name><name><surname>Loehrer</surname><given-names>PJ</given-names></name><name><surname>Wakelee</surname><given-names>HA</given-names></name></person-group><article-title>A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies</article-title><source>Lung Cancer</source><year>2015</year><volume>89</volume><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">26009269</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haura</surname><given-names>EB</given-names></name><name><surname>Tanvetyanon</surname><given-names>T</given-names></name><name><surname>Chiappori</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Simon</surname><given-names>G</given-names></name><name><surname>Antonia</surname><given-names>S</given-names></name><name><surname>Gray</surname><given-names>J</given-names></name><name><surname>Litschauer</surname><given-names>S</given-names></name><name><surname>Tetteh</surname><given-names>L</given-names></name><name><surname>Neuger</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Rawal</surname><given-names>B</given-names></name><name><surname>Schell</surname><given-names>MJ</given-names></name><name><surname>Bepler</surname><given-names>G</given-names></name></person-group><article-title>Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>1387</fpage><lpage>1394</lpage><pub-id pub-id-type="pmid">20142592</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isakoff</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Campone</surname><given-names>M</given-names></name><name><surname>Calles</surname><given-names>A</given-names></name><name><surname>Leip</surname><given-names>E</given-names></name><name><surname>Turnbull</surname><given-names>K</given-names></name><name><surname>Bardy-Bouxin</surname><given-names>N</given-names></name><name><surname>Duvillie</surname><given-names>L</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name></person-group><article-title>Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study</article-title><source>Br J Cancer</source><year>2014</year><volume>111</volume><fpage>2058</fpage><lpage>2066</lpage><pub-id pub-id-type="pmid">25290090</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>FM</given-names></name><name><surname>Bekele</surname><given-names>BN</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Wistuba</surname><given-names>I</given-names></name><name><surname>Tang</surname><given-names>XM</given-names></name><name><surname>Tran</surname><given-names>HT</given-names></name><name><surname>Erasmus</surname><given-names>JJ</given-names></name><name><surname>Hwang</surname><given-names>LL</given-names></name><name><surname>Takebe</surname><given-names>N</given-names></name><name><surname>Blumenschein</surname><given-names>GR</given-names></name><name><surname>Lippman</surname><given-names>SM</given-names></name><name><surname>Stewart</surname><given-names>DJ</given-names></name></person-group><article-title>Phase II study of dasatinib in patients with advanced non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>4609</fpage><lpage>4615</lpage><pub-id pub-id-type="pmid">20855820</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>ML</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Azzoli</surname><given-names>CG</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Sima</surname><given-names>CS</given-names></name><name><surname>Ginsberg</surname><given-names>MS</given-names></name><name><surname>Pao</surname><given-names>W</given-names></name><name><surname>Miller</surname><given-names>VA</given-names></name></person-group><article-title>Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib</article-title><source>J Thorac Oncol</source><year>2011</year><volume>6</volume><fpage>1128</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">21623279</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kluger</surname><given-names>HM</given-names></name><name><surname>Dudek</surname><given-names>AZ</given-names></name><name><surname>McCann</surname><given-names>C</given-names></name><name><surname>Ritacco</surname><given-names>J</given-names></name><name><surname>Southard</surname><given-names>N</given-names></name><name><surname>Jilaveanu</surname><given-names>LB</given-names></name><name><surname>Molinaro</surname><given-names>A</given-names></name><name><surname>Sznol</surname><given-names>M</given-names></name></person-group><article-title>A phase 2 trial of dasatinib in advanced melanoma</article-title><source>Cancer</source><year>2011</year><volume>117</volume><fpage>2202</fpage><lpage>2208</lpage><pub-id pub-id-type="pmid">21523734</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>EL</given-names></name><name><surname>Baurain</surname><given-names>JF</given-names></name><name><surname>Sparano</surname><given-names>J</given-names></name><name><surname>Strauss</surname><given-names>L</given-names></name><name><surname>Campone</surname><given-names>M</given-names></name><name><surname>Fumoleau</surname><given-names>P</given-names></name><name><surname>Rugo</surname><given-names>H</given-names></name><name><surname>Awada</surname><given-names>A</given-names></name><name><surname>Sy</surname><given-names>O</given-names></name><name><surname>Llombart-Cussac</surname><given-names>A</given-names></name></person-group><article-title>A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>6897</fpage><lpage>6904</lpage><pub-id pub-id-type="pmid">21903773</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeish</surname><given-names>IA</given-names></name><name><surname>Ledermann</surname><given-names>JA</given-names></name><name><surname>Webber</surname><given-names>L</given-names></name><name><surname>James</surname><given-names>L</given-names></name><name><surname>Kaye</surname><given-names>SB</given-names></name><name><surname>Hall</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>G</given-names></name><name><surname>Clamp</surname><given-names>A</given-names></name><name><surname>Earl</surname><given-names>H</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Kristeleit</surname><given-names>R</given-names></name><name><surname>Raja</surname><given-names>F</given-names></name><name><surname>Feeney</surname><given-names>A</given-names></name><name><surname>Lawrence</surname><given-names>C</given-names></name><name><surname>Dawson-Athey</surname><given-names>L</given-names></name><name><surname>Persic</surname><given-names>M</given-names></name><etal/></person-group><article-title>A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancerdagger</article-title><source>Ann Oncol</source><year>2014</year><volume>25</volume><fpage>1988</fpage><lpage>1995</lpage><pub-id pub-id-type="pmid">25070546</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>AA</given-names></name><name><surname>Pang</surname><given-names>H</given-names></name><name><surname>Hodgson</surname><given-names>L</given-names></name><name><surname>Ramnath</surname><given-names>N</given-names></name><name><surname>Otterson</surname><given-names>GA</given-names></name><name><surname>Kelley</surname><given-names>MJ</given-names></name><name><surname>Kratzke</surname><given-names>RA</given-names></name><name><surname>Vokes</surname><given-names>EE</given-names></name><collab>Cancer, Leukemia Group B</collab></person-group><article-title>A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602)</article-title><source>J Thorac Oncol</source><year>2010</year><volume>5</volume><fpage>380</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">20087228</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reardon</surname><given-names>DA</given-names></name><name><surname>Vredenburgh</surname><given-names>JJ</given-names></name><name><surname>Desjardins</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>KB</given-names></name><name><surname>Sathornsumetee</surname><given-names>S</given-names></name><name><surname>Threatt</surname><given-names>S</given-names></name><name><surname>Sampson</surname><given-names>JH</given-names></name><name><surname>Herndon</surname><given-names>JE</given-names><suffix>2nd</suffix></name><name><surname>Coan</surname><given-names>A</given-names></name><name><surname>McSherry</surname><given-names>F</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name><name><surname>McLendon</surname><given-names>RE</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Friedman</surname><given-names>HS</given-names></name></person-group><article-title>Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma</article-title><source>J Neurooncol</source><year>2012</year><volume>108</volume><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">22407177</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>SM</given-names></name><name><surname>Kopetz</surname><given-names>S</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Parikh</surname><given-names>N</given-names></name><name><surname>Qiao</surname><given-names>W</given-names></name><name><surname>Overman</surname><given-names>MJ</given-names></name><name><surname>Fogelman</surname><given-names>D</given-names></name><name><surname>Shureiqi</surname><given-names>I</given-names></name><name><surname>Jacobs</surname><given-names>C</given-names></name><name><surname>Malik</surname><given-names>Z</given-names></name><name><surname>Jimenez</surname><given-names>CA</given-names></name><name><surname>Wolff</surname><given-names>RA</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name><name><surname>Gallick</surname><given-names>G</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name></person-group><article-title>Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer</article-title><source>Invest New Drugs</source><year>2015</year></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schilder</surname><given-names>RJ</given-names></name><name><surname>Brady</surname><given-names>WE</given-names></name><name><surname>Lankes</surname><given-names>HA</given-names></name><name><surname>Fiorica</surname><given-names>JV</given-names></name><name><surname>Shahin</surname><given-names>MS</given-names></name><name><surname>Zhou</surname><given-names>XC</given-names></name><name><surname>Mannel</surname><given-names>RS</given-names></name><name><surname>Pathak</surname><given-names>HB</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Alpaugh</surname><given-names>RK</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name><name><surname>Godwin</surname><given-names>AK</given-names></name></person-group><article-title>Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study</article-title><source>Gynecol Oncol</source><year>2012</year><volume>127</volume><fpage>70</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">22710075</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>MR</given-names></name><name><surname>Wroblewski</surname><given-names>K</given-names></name><name><surname>Polite</surname><given-names>BN</given-names></name><name><surname>Knost</surname><given-names>JA</given-names></name><name><surname>Wallace</surname><given-names>JA</given-names></name><name><surname>Modi</surname><given-names>S</given-names></name><name><surname>Sleckman</surname><given-names>BG</given-names></name><name><surname>Taber</surname><given-names>D</given-names></name><name><surname>Vokes</surname><given-names>EE</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><name><surname>Kindler</surname><given-names>HL</given-names></name></person-group><article-title>Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium</article-title><source>Invest New Drugs</source><year>2012</year><volume>30</volume><fpage>1211</fpage><lpage>1215</lpage><pub-id pub-id-type="pmid">21552992</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonasch</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Rathmell</surname><given-names>WK</given-names></name></person-group><article-title>Renal cell carcinoma</article-title><source>BMJ</source><year>2014</year><volume>349</volume><fpage>g4797</fpage><pub-id pub-id-type="pmid">25385470</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Jonasch</surname><given-names>E</given-names></name><name><surname>Agarwal</surname><given-names>N</given-names></name><name><surname>Beard</surname><given-names>C</given-names></name><name><surname>Bhayani</surname><given-names>S</given-names></name><name><surname>Bolger</surname><given-names>GB</given-names></name><name><surname>Chang</surname><given-names>SS</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Costello</surname><given-names>BA</given-names></name><name><surname>Derweesh</surname><given-names>IH</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Hancock</surname><given-names>SL</given-names></name><name><surname>Kim</surname><given-names>JJ</given-names></name><name><surname>Kuzel</surname><given-names>TM</given-names></name><name><surname>Lam</surname><given-names>ET</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><etal/></person-group><article-title>Kidney cancer, version 3. 2015</article-title><source>J Natl Compr Canc Netw</source><year>2015</year><volume>13</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">25691606</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name></person-group><article-title>Resistance to targeted therapy in renal-cell carcinoma</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>992</fpage><lpage>1000</lpage><pub-id pub-id-type="pmid">19796751</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garnett</surname><given-names>MJ</given-names></name><name><surname>Edelman</surname><given-names>EJ</given-names></name><name><surname>Heidorn</surname><given-names>SJ</given-names></name><name><surname>Greenman</surname><given-names>CD</given-names></name><name><surname>Dastur</surname><given-names>A</given-names></name><name><surname>Lau</surname><given-names>KW</given-names></name><name><surname>Greninger</surname><given-names>P</given-names></name><name><surname>Thompson</surname><given-names>IR</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Soares</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Iorio</surname><given-names>F</given-names></name><name><surname>Surdez</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Milano</surname><given-names>RJ</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Systematic identification of genomic markers of drug sensitivity in cancer cells</article-title><source>Nature</source><year>2012</year><volume>483</volume><fpage>570</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">22460902</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suwaki</surname><given-names>N</given-names></name><name><surname>Vanhecke</surname><given-names>E</given-names></name><name><surname>Atkins</surname><given-names>KM</given-names></name><name><surname>Graf</surname><given-names>M</given-names></name><name><surname>Swabey</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Schraml</surname><given-names>P</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Cassidy</surname><given-names>AM</given-names></name><name><surname>Brewer</surname><given-names>D</given-names></name><name><surname>Al-Lazikani</surname><given-names>B</given-names></name><name><surname>Workman</surname><given-names>P</given-names></name><name><surname>De-Bono</surname><given-names>J</given-names></name><name><surname>Kaye</surname><given-names>SB</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Gore</surname><given-names>ME</given-names></name><etal/></person-group><article-title>A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma</article-title><source>Sci Transl Med</source><year>2011</year><volume>3</volume><fpage>85ra47</fpage></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araujo</surname><given-names>J</given-names></name><name><surname>Logothetis</surname><given-names>C</given-names></name></person-group><article-title>Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors</article-title><source>Cancer Treat Rev</source><year>2010</year><volume>36</volume><fpage>492</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">20226597</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buettner</surname><given-names>R</given-names></name><name><surname>Mesa</surname><given-names>T</given-names></name><name><surname>Vultur</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>F</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name></person-group><article-title>Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells</article-title><source>Mol Cancer Res</source><year>2008</year><volume>6</volume><fpage>1766</fpage><lpage>1774</lpage><pub-id pub-id-type="pmid">19010823</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homsi</surname><given-names>J</given-names></name><name><surname>Cubitt</surname><given-names>CL</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Munster</surname><given-names>PN</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Sullivan</surname><given-names>DM</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name><name><surname>Messina</surname><given-names>JL</given-names></name><name><surname>Daud</surname><given-names>AI</given-names></name></person-group><article-title>Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma</article-title><source>Melanoma Res</source><year>2009</year><volume>19</volume><fpage>167</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">19434004</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>JQ</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Buettner</surname><given-names>R</given-names></name><name><surname>Mirosevich</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>FY</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name></person-group><article-title>Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>9185</fpage><lpage>9189</lpage><pub-id pub-id-type="pmid">16230377</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shor</surname><given-names>AC</given-names></name><name><surname>Keschman</surname><given-names>EA</given-names></name><name><surname>Lee</surname><given-names>FY</given-names></name><name><surname>Muro-Cacho</surname><given-names>C</given-names></name><name><surname>Letson</surname><given-names>GD</given-names></name><name><surname>Trent</surname><given-names>JC</given-names></name><name><surname>Pledger</surname><given-names>WJ</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name></person-group><article-title>Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>2800</fpage><lpage>2808</lpage><pub-id pub-id-type="pmid">17363602</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byers</surname><given-names>LA</given-names></name><name><surname>Sen</surname><given-names>B</given-names></name><name><surname>Saigal</surname><given-names>B</given-names></name><name><surname>Diao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Nanjundan</surname><given-names>M</given-names></name><name><surname>Cascone</surname><given-names>T</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name><name><surname>Johnson</surname><given-names>FM</given-names></name></person-group><article-title>Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>6852</fpage><lpage>6861</lpage><pub-id pub-id-type="pmid">19861436</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>NP</given-names></name><name><surname>Kasap</surname><given-names>C</given-names></name><name><surname>Weier</surname><given-names>C</given-names></name><name><surname>Balbas</surname><given-names>M</given-names></name><name><surname>Nicoll</surname><given-names>JM</given-names></name><name><surname>Bleickardt</surname><given-names>E</given-names></name><name><surname>Nicaise</surname><given-names>C</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><article-title>Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis</article-title><source>Cancer Cell</source><year>2008</year><volume>14</volume><fpage>485</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">19061839</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>PA</given-names></name><name><surname>Grandis</surname><given-names>JR</given-names></name></person-group><article-title>STAT3 signaling: anticancer strategies and challenges</article-title><source>Mol Interv</source><year>2011</year><volume>11</volume><fpage>18</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">21441118</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>B</given-names></name><name><surname>Saigal</surname><given-names>B</given-names></name><name><surname>Parikh</surname><given-names>N</given-names></name><name><surname>Gallick</surname><given-names>G</given-names></name><name><surname>Johnson</surname><given-names>FM</given-names></name></person-group><article-title>Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>1958</fpage><lpage>1965</lpage><pub-id pub-id-type="pmid">19223541</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name></person-group><article-title>The STATs of cancer-new molecular targets come of age</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">14964307</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>P</given-names></name><name><surname>Turkson</surname><given-names>J</given-names></name></person-group><article-title>Targeting STAT3 in cancer: how successful are we?</article-title><source>Expert Opin Investig Drugs</source><year>2009</year><volume>18</volume><fpage>45</fpage><lpage>56</lpage></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyner</surname><given-names>JW</given-names></name><name><surname>Bumm</surname><given-names>TG</given-names></name><name><surname>Deininger</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>L</given-names></name><name><surname>Aichberger</surname><given-names>KJ</given-names></name><name><surname>Loriaux</surname><given-names>MM</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Burns</surname><given-names>CJ</given-names></name><name><surname>Fantino</surname><given-names>E</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name></person-group><article-title>CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>5232</fpage><lpage>5240</lpage><pub-id pub-id-type="pmid">20385788</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehar</surname><given-names>J</given-names></name><name><surname>Stockwell</surname><given-names>BR</given-names></name><name><surname>Giaever</surname><given-names>G</given-names></name><name><surname>Nislow</surname><given-names>C</given-names></name></person-group><article-title>Combination chemical genetics</article-title><source>Nat Chem Biol</source><year>2008</year><volume>4</volume><fpage>674</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">18936752</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Halder</surname><given-names>G</given-names></name></person-group><article-title>The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment</article-title><source>Nat Rev Drug Discov</source><year>2014</year><volume>13</volume><fpage>63</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">24336504</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Bossuyt</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Qiu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Halder</surname><given-names>G</given-names></name><name><surname>Finegold</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names></name></person-group><article-title>Hippo signaling is a potent <italic>in vivo</italic> growth and tumor suppressor pathway in the mammalian liver</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><fpage>1437</fpage><lpage>1442</lpage><pub-id pub-id-type="pmid">20080689</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Xia</surname><given-names>F</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Payer</surname><given-names>B</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Lauwers</surname><given-names>GY</given-names></name><name><surname>Thasler</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>JT</given-names></name><name><surname>Avruch</surname><given-names>J</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name></person-group><article-title>Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene</article-title><source>Cancer Cell</source><year>2009</year><volume>16</volume><fpage>425</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">19878874</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>M</given-names></name><name><surname>Ishiguro</surname><given-names>F</given-names></name><name><surname>Tanaka</surname><given-names>I</given-names></name><name><surname>Kondo</surname><given-names>Y</given-names></name><name><surname>Akatsuka</surname><given-names>S</given-names></name><name><surname>Toyokuni</surname><given-names>S</given-names></name><name><surname>Yokoi</surname><given-names>K</given-names></name><name><surname>Osada</surname><given-names>H</given-names></name><name><surname>Sekido</surname><given-names>Y</given-names></name></person-group><article-title>YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>5117</fpage><lpage>5122</lpage><pub-id pub-id-type="pmid">22286761</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research N</collab></person-group><article-title>Comprehensive molecular characterization of clear cell renal cell carcinoma</article-title><source>Nature</source><year>2013</year><volume>499</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">23792563</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>DD</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Krall</surname><given-names>EB</given-names></name><name><surname>Bhutkar</surname><given-names>A</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Schinzel</surname><given-names>AC</given-names></name><name><surname>Sood</surname><given-names>S</given-names></name><name><surname>Rosenbluh</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Zwang</surname><given-names>Y</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><article-title>KRAS and YAP1 converge to regulate EMT and tumor survival</article-title><source>Cell</source><year>2014</year><volume>158</volume><fpage>171</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">24954536</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>A</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Hua</surname><given-names>S</given-names></name><name><surname>Liewen</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Sadanandam</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>Q</given-names></name><name><surname>Chu</surname><given-names>GC</given-names></name><name><surname>Al-Khalil</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Fletcher-Sananikone</surname><given-names>E</given-names></name><etal/></person-group><article-title>Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer</article-title><source>Cell</source><year>2014</year><volume>158</volume><fpage>185</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">24954535</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horiguchi</surname><given-names>A</given-names></name><name><surname>Oya</surname><given-names>M</given-names></name><name><surname>Marumo</surname><given-names>K</given-names></name><name><surname>Murai</surname><given-names>M</given-names></name></person-group><article-title>STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P</article-title><source>Kidney Int</source><year>2002</year><volume>61</volume><fpage>926</fpage><lpage>938</lpage><pub-id pub-id-type="pmid">11849447</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horiguchi</surname><given-names>A</given-names></name><name><surname>Oya</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>T</given-names></name><name><surname>Uchida</surname><given-names>A</given-names></name><name><surname>Marumo</surname><given-names>K</given-names></name><name><surname>Murai</surname><given-names>M</given-names></name></person-group><article-title>Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome</article-title><source>J Urol</source><year>2002</year><volume>168</volume><fpage>762</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">12131365</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>HG</given-names></name><name><surname>Cho</surname><given-names>IH</given-names></name><name><surname>Chung</surname><given-names>DH</given-names></name><name><surname>Yoon</surname><given-names>SH</given-names></name><name><surname>Yang</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Ye</surname><given-names>SK</given-names></name><name><surname>Chung</surname><given-names>MH</given-names></name></person-group><article-title>STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells</article-title><source>FASEB J</source><year>2005</year><volume>19</volume><fpage>1296</fpage><lpage>1298</lpage><pub-id pub-id-type="pmid">15919761</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlus</surname><given-names>MR</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>CJ</given-names></name></person-group><article-title>STAT3 and HIF1alpha cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells</article-title><source>Oncogene</source><year>2014</year><volume>33</volume><fpage>1670</fpage><lpage>1679</lpage><pub-id pub-id-type="pmid">23604114</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Joyce</surname><given-names>S</given-names></name><name><surname>Panahandeh</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>SM</given-names></name><name><surname>Maxwell</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gooding</surname><given-names>WE</given-names></name><name><surname>Johnson</surname><given-names>DE</given-names></name><name><surname>Grandis</surname><given-names>JR</given-names></name></person-group><article-title>Targeting Stat3 abrogates EGFR inhibitor resistance in cancer</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><fpage>4986</fpage><lpage>4996</lpage><pub-id pub-id-type="pmid">22825581</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Pollock</surname><given-names>NI</given-names></name><name><surname>Black</surname><given-names>J</given-names></name><name><surname>DeGrave</surname><given-names>KA</given-names></name><name><surname>Wheeler</surname><given-names>S</given-names></name><name><surname>Freilino</surname><given-names>ML</given-names></name><name><surname>Joyce</surname><given-names>S</given-names></name><name><surname>Lui</surname><given-names>VW</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Chiosea</surname><given-names>SI</given-names></name><name><surname>Grandis</surname><given-names>JR</given-names></name></person-group><article-title>JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth</article-title><source>Neoplasia</source><year>2015</year><volume>17</volume><fpage>256</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">25810010</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagaraj</surname><given-names>NS</given-names></name><name><surname>Washington</surname><given-names>MK</given-names></name><name><surname>Merchant</surname><given-names>NB</given-names></name></person-group><article-title>Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>483</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">21266529</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Yeh</surname><given-names>JI</given-names></name><name><surname>Ferris</surname><given-names>RL</given-names></name><name><surname>Johnson</surname><given-names>JT</given-names></name><name><surname>Duvvuri</surname><given-names>U</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Sahu</surname><given-names>N</given-names></name><name><surname>Joyce</surname><given-names>S</given-names></name><name><surname>Freilino</surname><given-names>ML</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Ly</surname><given-names>D</given-names></name><name><surname>Rapireddy</surname><given-names>S</given-names></name><name><surname>Etter</surname><given-names>JP</given-names></name><etal/></person-group><article-title>First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy</article-title><source>Cancer Discov</source><year>2012</year><volume>2</volume><fpage>694</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">22719020</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbluh</surname><given-names>J</given-names></name><name><surname>Nijhawan</surname><given-names>D</given-names></name><name><surname>Cox</surname><given-names>AG</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Neal</surname><given-names>JT</given-names></name><name><surname>Schafer</surname><given-names>EJ</given-names></name><name><surname>Zack</surname><given-names>TI</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Schinzel</surname><given-names>AC</given-names></name><name><surname>Shao</surname><given-names>DD</given-names></name><name><surname>Schumacher</surname><given-names>SE</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Cowley</surname><given-names>GS</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><etal/></person-group><article-title>beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis</article-title><source>Cell</source><year>2012</year><volume>151</volume><fpage>1457</fpage><lpage>1473</lpage><pub-id pub-id-type="pmid">23245941</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>MS</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Gilks</surname><given-names>B</given-names></name><name><surname>Swenerton</surname><given-names>K</given-names></name><name><surname>Kalloger</surname><given-names>S</given-names></name><name><surname>Santos</surname><given-names>J</given-names></name><name><surname>Ju</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Coombes</surname><given-names>KR</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Huntsman</surname><given-names>D</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Hennessy</surname><given-names>BT</given-names></name></person-group><article-title>Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><fpage>2852</fpage><lpage>2860</lpage><pub-id pub-id-type="pmid">20460476</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><article-title>The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><fpage>e108</fpage><pub-id pub-id-type="pmid">23558742</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref></ref-list></back></article>